Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Tumor-Agnostic 2Other solid neoplasm 2Genitourinary 2Breast 2Sarcoma 1Other hematologic neoplasm 1Other 1Lymphoid 1Endocrine 1Dermatologic 1CNS 1

Conditions

Skin Neoplasms 1Melanoma 1Gastrointestinal Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 193aldesleukin 145Interleukin-2 109fludarabine phosphate 106Temozolomide 83Dacarbazine 81fludarabine 80Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Carboplatin 48Magnetic Resonance Spectroscopy 47Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42atezolizumab 41Specimen Handling 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Aromatherapy × Dermatologic × Clear all
NCT03858855 2020-08-04

Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment

Ohio State University Comprehensive Cancer Center

Phase NA Completed
248 enrolled
DermatologicEndocrineGastrointestinal

Gastrointestinal Neoplasms, Melanoma, Skin Neoplasms, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡